ArticleInfection control and hospital epidemiology2017
Risk of Clostridium difficile Infection in Hematology-Oncology Patients Colonized With Toxigenic C. difficile.
Article in Infection control and hospital epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Prevalence ofFrontiers in cellular and infection microbiology · 2022Pooled it
- Article
- Using routine asymptomaticJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025Article
- Heterogeneity of Clostridioides difficile asymptomatic colonization prevalence: a systematic review and meta-analysis.Gut pathogens · 2025Article
- A systematic literature review and bayesian meta-analysis of oral vancomycin primary prophylaxis forAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Review
- Determination of Risk Factors for Infectious Diarrhea in Patients with Hematological Malignancy.Infection & chemotherapy · 2024Article
- Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Review
- Clostridium difficile Colonization Before and After Hospitalization in Children.Turkish archives of pediatrics · 2021Article
- Multi-organism gastrointestinal polymerase chain reaction positivity among pediatric transplant vs non-transplant populations: A single-center experience.Pediatric transplantation · 2020Article
- Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population.Infectious disease clinics of North America · 2019Review
- Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016.BMC infectious diseases · 2019Article
- Detection of toxigenicJournal of medical microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The prevalence of colonization with toxigenic Clostridium difficile among patients with hematological malignancies and/or bone marrow transplant at admission to a 566-bed academic medical care center was 9.3%, and 13.3% of colonized patients developed symptomatic disease during hospitalization. This population may benefit from targeted C. difficile infection control interventions. Infect Control Hosp Epidemiol 2017;38:718-720.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.